Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) / Musolino, A., Gori, S., Cavanna, L., Graiff, C., Frassoldati, A., Bria, E., Bisagni, G., Zambelli, A., Partesotti, G., Brandes, A., Bonetti, A., Moscetti, L., Zamagni, C., Rocca, A., Generali, D., Montemurro, F., Gianni, L., Tognetto, M., Maglietta, G., Todeschini, R.. - In: CANCER RESEARCH. - ISSN 1538-7445. - (2018), pp. OT1-03-03-OT1-03-03. [10.1158/1538-7445.SABCS17-OT1-03-03]
Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Musolino, A
Writing – Review & Editing
;
2018-01-01
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
